Annals of Hematology

, 89:201

Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide

  • Youngil Koh
  • Soo-Mee Bang
  • Jae Hoon Lee
  • Hwi-Joong Yoon
  • Young-Rok Do
  • Hun-Mo Ryoo
  • Nari Lee
  • Seok Jin Kim
  • Kihyun Kim
  • Sung-Soo Yoon
  • Jong-Ho Won
  • Yeung-Chul Mun
  • Moon-Hee Lee
  • Ki-Hyun Rhee
  • Hyo-Jung Kim
  • HyeonSeok Eom
  • Min Kyoung Kim
  • Hyun Chun Shin
  • Korean Multiple Myeloma Working Party
Original Article

DOI: 10.1007/s00277-009-0807-6

Cite this article as:
Koh, Y., Bang, SM., Lee, J.H. et al. Ann Hematol (2010) 89: 201. doi:10.1007/s00277-009-0807-6

Abstract

The frequency of thromboembolic events (TE) in Caucasian patients with multiple myeloma (MM) receiving thalidomide as the initial treatment has been reported to be 10~58% without prophylactic anticoagulation. Korean MM patients treated with thalidomide were studied to determine the frequency of TE and associated risk factors. A retrospective medical record review of the Korean MM registry from 25 centers in Korea between 2003 and 2007 was performed. We assessed the incidence of arterial and venous TE and the associated clinical parameters. Three hundred and sixty MM patients (median age 61 years, range 32–88 years) received thalidomide treatment. Fourteen patients (3.9%) developed TE: 12 had venous and two had arterial locations. The sites for the venous TE included lungs (seven), lower extremities (four), upper extremities (one), and neck (one). Arterial TE developed in cerebral and peripheral arteries each. No single clinical parameter such as prerequisite for the metabolic syndrome, disease status, and treatment regimen were predictive for the development of TE. The frequency of TE in patients who received thalidomide as initial therapy (7/155) was not different from those who received thalidomide for progressive or relapsed disease (7/205, p = 0.592). The frequency of TE during thalidomide treatment in Korean patients with MM was low. No significant clinical factor was found to be a risk factor. The subgroup requiring thromboprophylaxis among the Korean patients with MM, receiving thalidomide, needs to be clarified.

Keywords

Multiple myelomaThalidomideThromboembolism

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Youngil Koh
    • 1
  • Soo-Mee Bang
    • 2
  • Jae Hoon Lee
    • 3
  • Hwi-Joong Yoon
    • 4
  • Young-Rok Do
    • 5
  • Hun-Mo Ryoo
    • 6
  • Nari Lee
    • 7
  • Seok Jin Kim
    • 8
  • Kihyun Kim
    • 8
  • Sung-Soo Yoon
    • 1
  • Jong-Ho Won
    • 9
  • Yeung-Chul Mun
    • 10
  • Moon-Hee Lee
    • 11
  • Ki-Hyun Rhee
    • 12
  • Hyo-Jung Kim
    • 13
  • HyeonSeok Eom
    • 14
  • Min Kyoung Kim
    • 15
  • Hyun Chun Shin
    • 16
  • Korean Multiple Myeloma Working Party
  1. 1.Department of Internal medicineSeoul National University HospitalSeoulSouth Korea
  2. 2.Department of Internal MedicineSeoul National University Bundang HospitalSeongnam-siSouth Korea
  3. 3.Department of Internal MedicineGachon University Gil HospitalIncheonSouth Korea
  4. 4.Department of Internal MedicineKyung Hee University College of MedicineSeoulSouth Korea
  5. 5.Department of Internal MedicineDongsan Medical CenterDaeguSouth Korea
  6. 6.Department of Internal MedicineDaegu Catholic University School of MedicineDaeguSouth Korea
  7. 7.Department of Internal MedicineChonbuk National University HospitalJeonjuSouth Korea
  8. 8.Department of Internal MedicineSamsung Medical CenterSeoulSouth Korea
  9. 9.Department of Internal MedicineSoon Chun Hyang University HospitalSeoulSouth Korea
  10. 10.Department of Internal MedicineEwha Women’s University College of MedicineSeoulSouth Korea
  11. 11.Department of Internal MedicineInha University HospitalIncheonSouth Korea
  12. 12.Department of Internal MedicineHoly Family HospitalBucheonSouth Korea
  13. 13.Department of Internal medicineHallym University Medical CenterAnyangSouth Korea
  14. 14.Special Cancer ClinicNational Cancer CenterGoyangSouth Korea
  15. 15.Department of Internal MedicineYeungnam University Medical CenterDaeguSouth Korea
  16. 16.Department of Internal MedicineHallym University Chuncheon HospitalChuncheonSouth Korea